DRUG · Mapped RxNorm record
Cisplatin
Normalized identity: cisplatinView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
NCT01074970
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Rucaparib
Normalized identity: rucaparibView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Cisplatin
Normalized identity: cisplatinView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
CisplatinDRUG · verified · RxNorm: cisplatin
RucaparibDRUG · verified · RxNorm: rucaparib
CisplatinDRUG · verified · RxNorm: cisplatin
Sponsors & collaborators
Hoosier Cancer Research Networklead sponsor
Clovis Oncology, Inc.collaborator
Mapped research locations
IndianapolisIndiana, United States2AlbuquerqueNew Mexico, United States2Los AngelesCalifornia, United States1St LouisMissouri, United States1MiamiFlorida, United States1ClevelandOhio, United States1PortlandOregon, United States1AuroraColorado, United States1Las VegasNevada, United States1MemphisTennessee, United States1NorfolkVirginia, United States1HollywoodFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01074970 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.